Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis

Weiwei Zhu; Chunquan Liu; Chunting Tan; Jie Zhang

doi:10.1016/j.heliyon.2023.e23543

Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis

Heliyon. 2023 Dec 11;10(1):e23543. doi: 10.1016/j.heliyon.2023.e23543. eCollection 2024 Jan 15.

Authors

Weiwei Zhu¹, Chunquan Liu², Chunting Tan³, Jie Zhang¹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, China.
² Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, China.
³ Department of Pulmonary and Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, China.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial disease that cannot be cured, and treatment options for IPF are very limited. Early diagnosis, close monitoring of disease progression, and timely treatment are therefore the best options for patients due to the irreversibility of IPF. Effective markers help doctors judge the development and prognosis of disease. Recent research on traditional biomarkers (KL-6, SP-D, MMP-7, TIMPs, CCL18) has provided novel ideas for predicting disease progression and prognosis. Some emerging biomarkers (HE4, GDF15, PRDX4, inflammatory cells, G-CSF) also provide more possibilities for disease prediction. In addition to markers in serum and bronchoalveolar lavage fluid (BALF), some improvements related to the GAP model and chest HRCT also show good predictive ability for disease prognosis.

Keywords: Biomarkers; Gender-age-physiology; HRCT; Idiopathic pulmonary fibrosis.

Publication types

Review